title: Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.
abstract: BACKGROUND
  Due to the association of second generation antipsychotics (SGAs) with weight gain and alterations of glucose and lipid homeostasis, we aimed to group six commonly prescribed SGAs into classes of differing risks.
  
  
  METHODS
  Twenty-eight patients meeting the criteria for a diagnosis of schizophrenic disorder according to ICD-10 were assigned to monotherapy with olanzapine, clozapine, quetiapine, amisulpride, ziprasidone or risperidone. The levels of glucose and lipid metabolism were assessed before and after 28 days of treatment.
  
  
  RESULTS
  Based on cluster analysis, olanzapine and clozapine were found to constitute a high-risk group for metabolic dysregulation while amisulpride, quetiapine, risperidone and ziprasidone could be assigned to a non-high-risk group. Subjects from the high-risk group displayed significant weight gain with concomitant increases of HOMA-IR, levels of insulin, total cholesterol, TG, LDL-C and leptin. No significant changes were observed in the non-high-risk group.
  
  
  CONCLUSIONS
  The results of this study support the conclusion of the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes that certain SGAs are associated with a higher risk for weight gain, insulin resistance and dyslipidemia.
authors.affiliation: Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Tschoner
authors.forename: J
authors.initials: J
authors.lastname: Engl
authors.forename: M
authors.initials: M
authors.lastname: Rettenbacher
authors.forename: M
authors.initials: M
authors.lastname: Edlinger
authors.forename: S
authors.initials: S
authors.lastname: Kaser
authors.forename: T
authors.initials: T
authors.lastname: Tatarczyk
authors.forename: M
authors.initials: M
authors.lastname: Effenberger
authors.forename: J R
authors.initials: JR
authors.lastname: Patsch
authors.forename: W W
authors.initials: WW
authors.lastname: Fleischhacker
authors.forename: C F
authors.initials: CF
authors.lastname: Ebenbichler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D016000:Cluster Analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D038801:International Classification of Diseases; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D018709:Statistics, Nonparametric; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose